CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,125.0%, EPS fell 66.7% and free cash flow fell 67.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow CGON
CG Oncology, Inc. (CGON) EV/Sales
As of 16 October 2026, CG Oncology, Inc. (CGON) trades at a EV/Sales of 684×. Over the past ten years it has ranged from 0.0× (March 2024) to 3,525× (September 2025); the current reading is higher than 8% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 551× | (41.07%) |
| FY2024 | 936× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 843× | (7.24%) |
| Mar 2026 | 909× | 64.80% |
| Dec 2025 | 551× | (49.53%) |
| Sep 2025 | 1,093× | (39.36%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KOD Kodiak Sciences Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.6× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| LGND Ligand Pharmaceuticals Incorporated compare | 19.8× |
| COGT Cogent Biosciences, Inc. compare | 193× |
| CRSP CRISPR Therapeutics AG compare | 223× |
| CGON CG Oncology, Inc. | 684× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)